Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1077-1084

  Gridelli, Cesare ^a   Frontini, Luciano ^b   Barletta, Emiddio ^a   Rossi, Antonio ^c   Barzelloni, Maria Luisa ^a   Scognamiglio, Francesco ^a   Guida, Cesare ^a   Gatani, Tindaro ^a   Fiore, Francesco ^a   De Bellis, Mario ^a   Marfella, A ^a   Manzione, Luigi ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

^c SAN CARLO HOSPITAL   (Italy)

Author keywords

Docetaxel; Non small cell lung cancer; Phase II study; Second line chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METOCLOPRAMIDE; NAVELBINE; PREDNISONE; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS;

EID: 17344386390     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. Br Med J 311: 899-909, 1995.
2. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non small cell lung cancer. J Clin Oncol 15: 2996-3018, 1997.
3. Francis PA, Rigas JR and Kris MG: Phase II trial of docetaxel in patients with stage III and IV non small cell lung cancer. J Clin Oncol 12: 1232-1237, 1994.
4. Rigas JR: Docetaxel in stage III and IV non small cell lung cancer. Eur J Cancer 31A (suppl 4): 518-520, 1995.
5. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Geisson B, Chasen M, Hong WK and Raber M: Phase II study of docetaxel for advanced or metastatic platinum-refractory non small cell lung cancer. J Clin Oncol 13: 645-651, 1995.
6. Alexopoulos K, Kouroussis L, Androulakis N, Papadimis E, Vaszlamatzis M, Kakolyris S, Samelis G, Patila E, Vossos A, Samantas E and Georgoulias V: Docetaxel and granulocyte colony-stimulating factors in patients with advanced non small cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial. Cancer Chemother Pharmacol 43: 257-262, 1999.
7. Miller AB, Hoogstraten B, Stoquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
8. Eagan RT, Frytak S, Richardson RL, Crcagan ET and Nichols WC: Phase II study of the three-drug combination of mitomycin C, CCNU, and methotrexate (MCM) in advanced non small cell lung cancer. Am J Clin Oncol 9: 67-70, 1986.
9. Klastersky J, Sculier JP, Mommen P, Ravez P, Libert P, Vandermoten G, Beequart D and Schmerber J: Combination chemotherapy with mitomycin C and vindesine in the treatment of non small cell lung carcinoma (NSCLC). Proc Am Ass Cancer Res, 26: 153, 1985.
10. Gridelli C, Airoma G, Incoronato P, Pepe R, Palazzolo G, Rossi A and Bianco AR: Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non small cell lung cancer. Cancer Chemother Pharmacol 30: 212-214, 1992.
11. 2) plus vindesine is not an effective salvage regimen for advanced non small cell lung cancer priorly treated by a cisplatinum containing regimen. Lung Cancer 11 (suppl 1): 127, 1994.
12. Chen YM, Liu JM, Wm MF, Lin WG, Tsai CH, Pcrng RP and Whang-Peng J: Ifosfamide-based chemotherapy for previusoly treated lung cancer patients. Chung Kua I Husseh Tsa Chih 61: 389-396, 1998.
13. Jacoulet P, Depierre A, Dubiez A, Dalphin JC and Debleuvre D: Results of cisplatin-etoposide chemotherapy following navelbine in non small cell lung cancer. Proc Am Soc Clin Oncol 10: 253, 1991.
14. Miller VA, Rigas JR, Pisters KMW, Pfister DG, Heelan RT and Kris MG: Ifosfamide plus high-dose cisplatin in patients with non small cell lung cancer previously treated with chemotherapy. Am J Clin Oncol 18: 303-306, 1995.
15. Albain KS, Bitran JD, Colomb HM, Hoffman PC, Demeester TR, Skosen C, Noble S and Blongh RR: Trial of vindesine, etoposide and cisplatin in patients with previously treated advanced stage, non small cell bronchogenic carcinoma. Cancer Treat Rep 68: 413-415, 1984.
16. Kunitoh H, Maeda A, Nakamura Y, Yamamoto N, Kasai T, Sekine I, Kubota K, Tamura T, Shinkai T, Kodama T and Saijo N: Mitomycin C, vindesine and cisplatin (MVP) combination as a salvage chemotherapy in pretreated non small cell lung cancer (NSCLC) patients (pts). Proc Am Soc Clin Oncol 17: 491a, 1998.
17. Dansin E, Sokpoh H, Georger H, Bevar JF, Stach B and Lafitte JJ: Mitomycin, ifostamide, cisplatin (MIC) as second line regimen in advanced non small cell lung cancer (NSCLC). Ann Oncol 3(suppl 5): 35, 1992.
18. Riviere A, Berille J, Monnier A, Pujol SL, Cerrina ML and Le Chevalier T: Fotomustine salvage treatment in non small cell lung cancer (NSCLC): interim report of a phase II study. Ann Oncol 1(suppl): 58, 1990.
19. Papadakis E, Kourousis CH, Androulakis N, Agelahi S, Apostolopoulou F, Palamidas F, Rapti A, Sarra K, Tziani V, Bania E, Agelidou A, Gianakakis T, Kandilis K, .Andravanis A, Apostolaki F and Georgoulias V: Second-line treatment of non small cell lung carcinomas with vinorelbine and ifosfamide: preliminary results of a phase II dial of the Greek Cooperative Group for Lung Cancer. Lung Cancer 21(suppl 1): S36, 1998.
20. Murphy WK, Winn RJ, Huber M, Fossella FV, Goldberg D, Presant CA, Flynn PJ, Goldman B, Clements S, Raber M and Hong WK: Phase II study of taxol (T) in patients (pt) with non small cell lung cancer (NSCLC) who have failed platinum containing chemotherapy (CTX). Proc Am Soc Clin Oncol 13: 363, 1994.
21. Socinski MA and Steagall A: Phase II trial of 96-hour paclitaxel (P) infusion in patients (pts) with non small cell lung cancer (NSCLC) failing previuos platinum-based or short duration paclitaxel therapy. Proc Am Soc Clin Oncol 16: 428a, 1997.
22. Nauman C, Delaney TF, Park J and Zaner KS: Paclitaxel (taxol) as a single agent salvage therapy in non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16: 476a, 1997.
23. Stathopoulos GP, Rigatos S and Malamos NA: Paclitaxel combined with cisplatin as second-line traetment in patients with advanced non small cell lung cancers refractory to cisplatin. Oncol Rep 6: 797-800, 1990.
24. Roa V, Conner A and Mitchell RB: Carboplatin and paclitaxel for previously treated patients with non small cell lung cancer. Cancer Invest 16: 381-384, 1998.
25. Crinó L, Mosconi AM, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, Della Giulia M, Gridelli C, Rossi A, Calandri C, De Marinis F, Noseda M and Tonato M: Gemcitabine as second line treatment for advanced non small cell lung cancer: a phase II trial. J Clin Oncol 17: 2081-2085, 1999.
26. Gridelli C, Perrone F, Gallo C, Rossi A, Barletta E, Barzelloni ML, Creazzola S, Gatani T, Fiore F, Guida C and Scognamiglio F: Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial. Anticancer Res 19: 4535-4538, 1999.
27. Guerra J, Arcediano A, Lianes P, Castellano D, Paz-Ares L, Gomez-Martin C and Cortes-Funes H: Improvement of disease-related symptoms with second line of gemcitabine in advanced non small cell lung cancer (NSCLC). Ann Oncol 9(suppl 4): 95, 1998.
28. Cassano A, Corsi DC, Pozzo C, Angeletti L, Ferretti G, Longo R and Barone C: Gemcitabine (GEM) as rescue treatment of advanced non small cell lung cancer (NSCLC). Effect on brain metastases. Ann Oncol 9(suppl 2): 163, 1998.
29. Rosvold E, Langer CJ, Schilder R, Millenson M, Reimet E and Kreamer K: Salvage therapy with gemcitabine in advanced non small cell lung cancer (NSCLC) progressing after prior carboplatinpaclitaxel (C-P). Proc Am Soc Clin Oncol 17: 467a, 1998.
30. Garfield DH, Dakhil SR, Whittaker TL and Keller AM: Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non small cell lung cancer (A NSCLC). Proc Am Soc Clin Oncol 17: 484a, 1998.
31. Biesma B, Smit EF and Postmus PE: A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non small cell lung cancer after platinum containing chemotherapy. Lung Cancer 24: 115-121, 1999.
32. Androulakis N, Kouroussis L, Kakolyris S, Tzannes S, Papadakis E, Papadimitriou C, Geroyianni A, Georgopoulou T, Dimopoulou I, Souglakos J, Kotsakis A, Vardakis N, Hatzidaki D and Georgoulias V: Salvage treatment with paclitaxel and gemcitabine for patients with non small cell lung cancer after cisplatin or docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol 9: 1127-1130, 1998.
33. Barr F, Mirsky H, Clinthorne D, Bendel S and Smith F: A phase II .study of gemcitabine and vinorelbine salvage chemotherapy for taxane resistant non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18: 496a, 1999.
34. Gian V, Hainsworth JD, Burris HA, Erland JB, Brown CP, Rinaldi DA and Greco FA: Combination gemcitabine and vinorelbine in the second-line treatment of non small cell lung cancer (NSCLC): a phase II study of the Minnie Pearl Cancer Research Network. Proc Am Soc Clin Oncol 18: 505a, 1999.
35. Cole JL, Rinaldi DA, Lormand NA, Brierre JE, Barnes B, Fontenot MF, Buller EJ and Rainlev JM: A phase I-II trial of topotecan (TOP) and gemcitabine (GEM) for patients with previously treated, advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18: 499a, 1999.
36. Burris H, Eckhardt S and Fields S: Phase II trial of docetaxel in patients with non small cell lung cancer. Proc Am Soc Clin Oncol 12: 335, 1993.
37. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Ki Hong W and Raber M: Phase II study of docetaxel for advanced or metastatic platinum-refractory non small cell lung cancer. J Clin Oncol 13: 645-651, 1995.
38. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C: Activity of docetaxel in platinum-treated non small cell lung cancer: Results of a phase II multicenter trial. J Clin Oncol 18: 131-135, 2000.
39. Robinet G, Kleisbauer JP, Thomas P, Perol M, Carles P, Paillotin D, Lena H, Poirier R, Clovet P, Lenseigne S and Soares JA: Phase II study of docetaxel (taxotere) in first and second-line NSCLC. Proc Am Soc Clin Oncol 16: 480a, 1997.
40. 2 in platinum pretreated advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18: 518a, 1999.
41. 2 vs vinorelbine/ ifosfamide for non small cell lung cancer (NSCLC) previously treated with platinum based chemotherapy (PBC). Proc Am Soc Clin Oncol 18: 460a, 1999.
42. Shepherd F, Gralla R, Ramlau R, Mattson K, Berman B, Kraszko P, Rudd R, Berille J, Kim Y and Coughlin S: Randomized study of taxotere (TAX) versus best supportive care (BSC) in non small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. Eur J Cancer 35(suppl 4): S247, 1999.
43. Dancey J, Shepherd F, Ramlau R, Mattron K, Gressot L, O'Rourke M, Vincent M, Burker R, Levitau N, Bergman B, Krasko P, Baaz L, Ruold R, Kim Y, Coughlin S, Soussan-Lazard K and Gralla R: Quality of life(QoL) assessment in a randomized study of taxotere (TAX) versus best supportive care (BSC) in non small cell lung cancer (NSCLC) patients (pts) previously treated with platinum based chemotherapy. Proc Am Soc Clin Oncol 18: 491a, 1999.
44. Hotton K, Kim K, Larson ML, Larson MM, Pharo L and Schiller JH: Phase I-II trial of docetaxel and vinorelbine in patients with non small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 18: 509a, 1999.
45. Androulakis N, Papadakis E, Bania E, Apostolopulou F, Tsiafaki X, Kalofini SC, Rapti A, Touhis M, Chainis K, Kouroussis C, Sarra E, Vardakis N, Hatzidaki D and Georgoulias V: Second line treatment with docetaxel (D) and gemcitabine (G) in patients with advanced non small cell lung cancer (NSCLC): a multicenter phase II trial. Proc Am Soc Clin Oncol 18: 494a, 1999.